R A N B A X Yfinal
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
1,733
On Slideshare
1,733
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
29
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Ranbaxy Laboratories Ltd Presented by Sudip & Pradipta
  • 2. Company Highlights
    • Largest pharmaceutical company
    • FDA inspected and approved facilities.
    • Expertise in diverse categories
    • Expertise in OTC
    • Strengths and vibrancy
    • Other Expertise
  • 3. Timelines
    • 1962: Ranjit Singh and Gurbux Singh in Amritsar
    • 1977: First JV Nigeria
    • 1987: State-of-the-art API facility in Toansa in preparation for entry
    • into the U.S. market, receives FDA approval in 1988
    • 1992: Launches a joint marketing agreement with Eli Lilly
    • 1993: A joint venture is launched in China; a new research-driven
    • NCE and NDDS strategy launched
    • 1995: The company acquires Ohm Laboratories in the United
    • States and builds a new FDA-approved production facility
    • 2000: A cquires Basics, Bayer's generics business in Germany; the
    • company enters Brazil
    • 2003 : Acquires Aventis in France
    • Latest : Wish to acquire $2 Billion stake in Merck
  • 4. Internationalization
  • 5. International Biz
    • USA
    • Largest Healthcare market
    • Entered in 1995, now the largest market for the company
    • Acquire Ohm labs
    • 28% of Ranbaxy’s revenues
    • 96 products approved by FDA
  • 6.
    • ITALY(GSK) & SPAIN
    • Organic opportunities.
    • Bought Allen in Italy
    • Among top 10 global market.
    • Low penetration on generics.
    • Patents expiries happen later.
    • First movers advantage.
  • 7.
    • BELGIUM (Ethimed)
    • High priced and profitable market.
    • Market is not too large.
    • Existence of 10-12 products.
  • 8.
    • ROMANIA (Terapia)
    • Low cost market in terms of manufacturing.
    • Strategically well positioned.
    • Wide marketing authorizations.
    • Strong product portfolio.
    • Strong field force
  • 9. Managing the business
      • Created trade support & networks overseas
      • Confidence in generic drug business
      • Germany 4.8
      • UK 2.8
      • France 1.6
      • Italy 0.5
      • (major size of generics market in $ billion)
  • 10. Cont…
      • Allowed to diverse into new markets
      • Intangible assets
  • 11.
    • Thank You